Title: Patent blue violet-directed mapping and micrometastasis detection of sentinel lymph node in gastric cancer
Abstract: Objective:To investigate the feasibility and clinical significance of using patent blue violet-directed mapping for sentinel lymph node(SLN) detection in gastric cancer.Methods:Thirty four patients with gastric cancer, who underwent standard radical gastrectomy with lymphadenectomy (D2 or D3), were enrolled in this study. Before resection, patent blue violet was intraoperatively injected into subserosal or submucosal layer adjacent to the tumor. Blue stained nodes were defined as SLNs and analyzed by routine HE preparations. Those negative SLNs were examined with cytokeratin immunohistochemical staining. The incidence of metastasis in SLNs was compared with that in non-SLNs. The diagnostic accuracy and false negative rate of regional lymph node status on the basis of SLN status were calculated,respectively. Results:SLNs were detected in 32 of 34 patients with a success rate of 94.1%. The number of SLNs ranged from 1 to 3 in one case, with a mean value of 1.8 per case. The incidence of metastasis was significantly higher in SLNs than that in non-SLNs (55.1% vs 14.1%). The diagnostic accuracy and false negative rate were 93.7% and 8.3%, respectively. Focused analysis of SLN upstaged 2 cases of patients with gastric cancer. Conclusions:Patent blue violet-directed mapping of SLN in gastric cancer is technically feasible and may provide an accurate diagnostic procedure for detecting lymph node metastasis in patients with gastric cancer. Focused analysis of SLN may upstage gastric cancer.
Publication Year: 2006
Publication Date: 2006-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot